Download PDF
Dtsch Med Wochenschr 2012; 137(38): 1859-1872
DOI: 10.1055/s-0032-1305191
CME | Review article
Diabetologie, Pharmakotherapie
© Georg Thieme Verlag KG Stuttgart · New York

Orale Therapie des Diabetes mellitus Typ 2

Oral treatment of type 2 diabetes mellitus
K.-D. Palitzsch
1   Klinik für Endokrinologie, Diabetologie, Angiologie und Innere Medizin, Zentrale Notaufnahme, Klinikum Neuperlach, Städtisches Klinikum München GmbH
› Author Affiliations
Further Information

Publication History

22 February 2012

28 June 2012

Publication Date:
12 September 2012 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Epidemiologie - optimierte Stoffwechselkontrolle - Hypoglykämie - orale Antidiabetika - Nebenwirkungen

Keywords

epidemiology - optimal glycemic control - hypoglycemia - oral anti-diabetic medications - side effects
 

  • Literatur

  • 1 American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care 2011; 34 (Suppl. 01) 11-S61
    PubMedSearch in Google Scholar
  • 2 Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. systematic review and meta-analysis. JAMA 2007; 298: 194-206
    CrossrefPubMedSearch in Google Scholar
  • 3 Astrup A, Rössner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616
    CrossrefPubMedSearch in Google Scholar
  • 4 Bergenstal RM, Wysham C, MacConell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439
    CrossrefPubMedSearch in Google Scholar
  • 5 Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255-1261
    CrossrefPubMedSearch in Google Scholar
  • 6 Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47
    CrossrefPubMedSearch in Google Scholar
  • 7 Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643
    CrossrefPubMedSearch in Google Scholar
  • 8 DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549
    CrossrefPubMedSearch in Google Scholar
  • 9 Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289
    CrossrefPubMedSearch in Google Scholar
  • 10 Hughes RC, Rowan JA. Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?. Diabet Med 2006; 23: 318-322
    CrossrefPubMedSearch in Google Scholar
  • 11 Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136
    CrossrefPubMedSearch in Google Scholar
  • 12 Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203
    CrossrefPubMedSearch in Google Scholar
  • 13 Parks M, Rosebraugh C. Weighing Risks and Benefits of Liraglutide – The FDA´s review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-777
    CrossrefPubMedSearch in Google Scholar
  • 14 Schernthaner G, Matthews DR, Charbonell G et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076
    CrossrefPubMedSearch in Google Scholar
  • 15 Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-3354
    CrossrefPubMedSearch in Google Scholar
  • 16 Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576
    CrossrefPubMedSearch in Google Scholar
  • 17 Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012
    CrossrefPubMedSearch in Google Scholar
  • 18 UK Prospektive Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
    CrossrefPubMedSearch in Google Scholar
  • 19 United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165-175
    CrossrefPubMedSearch in Google Scholar